Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
8,187
datasets available to search
ShareScore release 0.7.1
Dataset results
8,187 results for “Lung cancer”
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT04644237. IPD Sharing: YES. Countries: 10. Publications: 2.
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04205812. IPD Sharing: YES. Countries: 17. Publications: 1.
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT01828099. IPD Sharing: YES. Countries: 29. Publications: 2.
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT03599518. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
ClinicalTrials.gov study NCT03596866. IPD Sharing: YES. Countries: 20. Publications: 2.
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT01685138. IPD Sharing: YES. Countries: 18. Publications: 2.
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT03505710. IPD Sharing: YES. Countries: 5. Publications: 3.
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT03255083. IPD Sharing: YES. Countries: 1. Publications: 2.
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
ClinicalTrials.gov study NCT03626545. IPD Sharing: YES. Countries: 26. Publications: 1.
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acr
ClinicalTrials.gov study NCT03447769. IPD Sharing: YES. Countries: 41. Publications: 1.
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
ClinicalTrials.gov study NCT04656652. IPD Sharing: YES. Countries: 26. Publications: 2.
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
ClinicalTrials.gov study NCT02733159. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
ClinicalTrials.gov study NCT03535740. IPD Sharing: YES. Countries: 15. Publications: 3.
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
ClinicalTrials.gov study NCT02335944. IPD Sharing: YES. Countries: 11. Publications: 2.
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT03807778. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
ClinicalTrials.gov study NCT02414139. IPD Sharing: YES. Countries: 20. Publications: 3.
Deciphering genomic evolution of metastatic organotropism with 535 paired primary lung cancers and metastases
<p>Scripts and processed data used in the analyses of the manuscript:</p> <p><em>Deciphering genomic evolution of metastatic organotropism with 535 paired primary lung cancers and metastases.</em></p>
Commonly asked questions for lung cancer screening
<p class="MsoNormal"><strong>Introduction.</strong> Lung cancer screening (LCS) can reduce lung cancer mortality; however, poor understanding of results may impact patient experience and follow-up. We sought to determine whether an informational handout accompanying LCS results can improve patient-reported outcomes and adherence to follow-up.</p> <p class="MsoNormal"><strong>Study Design.</strong> This was a prospective alternating intervention pilot trial of a handout to accompany LCS results delivery.</p> <p class="MsoNormal"><strong>Setting/Participants.</strong> Patients undergoing LCS in a multisite program over a 6-month period received a mailing containing either: 1) a standardized form letter of LCS results (control) or 2) the LCS results letter and the handout (intervention).</p> <p class="MsoNormal"><strong>Intervention.</strong> A two-sided informational handout on commonly asked questions after LCS was created through iterative mixed-methods evaluation with both LCS patients and providers.</p> <p class="MsoNormal"><strong>Outcome Measures.</strong> The primary outcomes of 1)patient understanding of LCS results, 2)correct identification of next steps in screening, and 3)patient distress were measured through survey. Adherence to recommended follow-up after LCS was determined through chart review. Outcomes were compared between the intervention and control group using generalized estimating equations.</p> <p class="MsoNormal"><strong>Results.</strong> 389 patients were eligible and enrolled with survey responses from 230 participants (59% response rate). We found no differences in understanding of results, identification of next steps in follow-up or distress but did find higher levels of knowledge and understanding on questions assessing individual components of LCS in the intervention group. Follow-up adherence was overall similar between the two arms, though was higher in the intervention group among those with positive findings (p=0.007).</p> <p class="MsoNormal"><strong>Conclusions.</strong> There were no differences in self-reported outcomes between the groups or overall follow-up adherence. Those receiving the intervention did report greater understanding and knowledge of key LCS components, and those with positive results had a higher rate of follow-up. This may represent a feasible component of a multi-level intervention to address knowledge and follow-up for LCS.</p>
Multi-breath 4DCT images of lung cancer patients
<p><strong>Multi-breath 4DCT images of six non-small cell lung cancer (NSCLC) patients.</strong></p><p>Breathing motion has been transferred across longitudinal imaging to generate new 4DCT images sampling five consecutive breaths.</p><p>This dataset is the result of processing six subjects selected from the 4D-Lung dataset published in The Cancer Imaging Archive: <a href="https://doi.org/10.7937/K9/TCIA.2016.ELN8YGLE">https://doi.org/10.7937/K9/TCIA.2016.ELN8YGLE </a>Hugo et al. (2016).</p><p>Data generated within the project "New concept for adaptive real time tumour tracking" funded by the Swiss National Science Foundation (SNSF) under grant agreement 200021_185082: <a href="https://data.snf.ch/grants/grant/185082">https://data.snf.ch/grants/grant/185082</a> </p><p> </p>
Molecular dynamics dataset for pharmacological repositioning in the treatment of non-small-cell lung cancer
<p><span>Non-small cell lung cancer (NSCLC) is a type of lung cancer associated with translocation of the EML4 and ALK genes on the short arm of chromosome 2. This leads to the development of an aberrant protein kinase with a deregulated catalytic domain, the cdALK<sup>+</sup>. Currently, different ALK inhibitors (iALKs) have been proposed to treat ALK<sup>+ </sup>NSCLC patients.</span> <span>However, the recent resistance to iALKs stimulates the exploration of new iALKs for NSCLC. Here, we describe an <em>in silico</em> approach to finding FDA-approved drugs that can be used by pharmacological repositioning as iALK. We used homology modelling to obtain a structural model of cdALK<sup>+</sup> protein and then performed molecular docking and molecular dynamics of the complex cdALK<sup>+</sup>-iALKs to generate the pharmacophore model. The pharmacophore was used to identify potential iALKs from FDA-approved drugs library by ligand-based virtual screening. Four pharmacophores with different atomistic characteristics were generated, resulting in six drugs that satisfied the proposed atomistic positions</span> <span>and coupled at the ATP-binding site. Mitoxantrone, riboflavin and abacavir exhibit the best interaction energies with 228.29, 165.40 and 133.48 kjoul/mol respectively. In addition, the special literature proposed these drugs for other types of diseases due to pharmacological repositioning. This study proposes FDA-approved drugs with ALK inhibitory characteristics. Moreover, we identified pharmacophores sites that can be tested with other pharmacological libraries</span><span>.</span></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.